Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.79 |
| ▸ | ACACA | Q13085 | 13/20 | 0.79 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12479491 | 0.91 | ACACB (0.77) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL12479133 | 0.90 | ACACB (0.64) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL12479148 | 0.88 | ACACB (0.76) | ACACBACACANTRK1FLT3GSK3B | |
| SCHEMBL16045105 | 0.88 | ACACB (1.00) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL14676053 | 0.88 | ACACB (0.78) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL16080656 | 0.88 | ACACB (1.00) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL16045104 | 0.88 | ACACB (1.00) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL14700733 | 0.88 | ACACB (0.78) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL2355252 | 0.88 | ACACB (0.78) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL14689498 | 0.88 | ACACB (0.81) | ACACBACACADAPK3NTRK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000026-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-07 | — | — | US | claimed |
| US-20140011853-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-09 | — | — | US | claimed |
| EP-2675788-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2013-12-25 | — | — | EP | claimed |
| WO-2012110518-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | WO | claimed |
| US-9000026-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000026-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000026-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8946124-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy and halogen-substituted spirocyclic ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946124-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy and halogen-substituted spirocyclic ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946124-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy and halogen-substituted spirocyclic ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140045696-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045696-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045696-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140011853-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-09 | — | — | US | disclosed |
| US-20140011853-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-09 | — | — | US | disclosed |
| US-20140011853-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-09 | — | — | US | disclosed |
| EP-2675789-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS | Bayer Intellectual Property GmbH (DE) | 2013-12-25 | — | — | EP | disclosed |
| EP-2675788-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012110518-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012110519-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS | BAYER CROPSCIENCE AG (DE) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045696-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS | DDT, PDHX, CYP8B1 | ACACB 904/4885ACACA 1096/4885DAPK3 946/4885 |
| US-20140011853-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | DDT, PDHA1, KCNH1 | ACACB 649/4885ACACA 866/4885DAPK3 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.